[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492842":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":42,"collaborators":20,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":64,"conditions":65,"keywords":20,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental","EXPERIMENTAL","Participants will receive an injection of 250 mM of hyperpolarized 13-C pyruvate intravenously after standard of care imaging sequences are performed. Then participants will undergo HP-MR imaging.",[13],"Drug: Hyperpolarized 13C-Pyruvate",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Hyperpolarized 13C-Pyruvate","Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.",[9],null,[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"University of Maryland Medical Center","RECRUITING","Baltimore","Maryland","21201","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-76.61219,39.29038,{"lat":34,"lon":33},[37],{"name":38,"role":39,"phone":40,"phoneExt":20,"email":41},"Rosy Njonkou, MA","CONTACT","410-706-0943","rnjonkou@som.umaryland.edu",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Vikas Kundra","Chief of Oncologic Imaging","100492842","phase-1-hp-pyruvate-mri-in-cancers-100492842",false,"NCT05697406","HP Pyruvate MRI in Cancers","Hyperpolarized 13-C Pyruvate MRI Surveillance of Multiple Cancers","HC-MRI","Inclusion Criteria:\n\nClinical tumor diagnosis\n\nPatients with pre-existing MR imaging appointments\n\nMust be able to undergo MR\n\nExclusion Criteria:\n\nNo tumor diagnosis","ALL","18 Years","88 Years",{"count":58,"type":59},25,"ESTIMATED","INTERVENTIONAL",[62,63],"PHASE1","PHASE2","Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruvate to lactate. This can be exploited by hyperpolarized imaging. Hyperpolarized 13C MRI imaging is an approach that utilizes a stable isotope of Carbon (13C) linked to pyruvate. MRI spectroscopy is used in conjunction with hyperpolarized 13C pyruvate in order to temporally detect pyruvate and its conversion to lactate in-vivo, in order to visualize downstream metabolic (glycolytic) activity secondary to the Warburg effect, which should be useful in detecting and characterizing tumors of various types. Hyperpolarized 13C pyruvate MR imaging has not been tested in most cancers. In this preliminary survey, we will test the hypothesis that hyperpolarized 13C pyruvate MR imaging can be used to image various cancers.",[66,67,68],"Image","Warburg Effect","Tumors","2025-09-16",{"date":71,"type":72},"2025-09-22","ACTUAL",{"date":74,"type":72},"2024-06-24",{"date":76,"type":59},"2028-12-01",{"name":5,"class":6},1]